{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:50:15Z","timestamp":1793303415541,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jtha.2024.12.034","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T12:38:23Z","timestamp":1736426303000},"page":"1516-1521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Accurate evaluation of factor VIII activity of efanesoctocog alfa in the presence of emicizumab"],"prefix":"10.1016","volume":"23","author":[{"given":"Christophe","family":"Nougier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W.","family":"Pipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Pabinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Pouplard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger E.G.","family":"Schutgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edison","family":"Sexton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Quehenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve-Anne","family":"Guery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Huisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Astrid","family":"Van Dievoet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Marquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4888-1463","authenticated-orcid":false,"given":"Yesim","family":"Dargaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.12.034_bib1","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.12.034_bib2","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 3","key":"10.1016\/j.jtha.2024.12.034_bib3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/hae.14976","article-title":"Benefits and risks of non-factor therapies: redefining haemophilia treatment goals in the era of new technologies","volume":"30","author":"Mancuso","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.12.034_bib4","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/17474086.2023.2293096","article-title":"Efficacy\/effectiveness and safety of emicizumab prophylaxis of people with hemophilia A: a systematic review and meta-analysis","volume":"16","author":"Muniz","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jtha.2024.12.034_bib5","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa2002699","article-title":"BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A","volume":"383","author":"Konkle","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.12.034_bib6","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.jtha.2024.04.010","article-title":"Ultra-long factor VIII: a major step forward toward a hemophilia-free mind","volume":"22","author":"Hermans","year":"2024","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.034_bib7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"von Drygalski","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.12.034_bib8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/17425255.2024.2409931","article-title":"Pharmacokinetic evaluation of efanesoctocog alfa: breakthrough factor VIII therapy for hemophilia A","volume":"21","author":"Yada","year":"2025","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.jtha.2024.12.034_bib9","first-page":"2436","article-title":"Efanesoctocog alfa: the renaissance of factor VIII replacement therapy","volume":"109","author":"Dargaud","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.12.034_bib10","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/hae.14177","article-title":"Effects of Emicizumab on APTT, FVIII assays and FVIII Inhibitor assays using different reagents: results of a UK NEQAS proficiency testing exercise","volume":"26","author":"Lowe","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.12.034_bib11","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/ijlh.14021","article-title":"The combination of emicizumab and recombinant factor VIII in plasma: which assays can we use for accurate measurement?","volume":"45","author":"Bowyer","year":"2023","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2024.12.034_bib12","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/ejh.13490","volume":"105","author":"Nougier","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2024.12.034_bib13","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/hae.14831","article-title":"A\u00a0global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories","volume":"30","author":"Pipe","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.12.034_bib14","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1046\/j.1365-2516.1998.440646.x","article-title":"Influence of phospholipids on the assessment of factor VIII activity","volume":"4","author":"Mikaelsson","year":"1998","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.12.034_bib16","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtha.2022.12.029","article-title":"Hemophilia treatment innovation: 50 years of progress and more to come","volume":"21","author":"Mannucci","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.034_bib17","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1055\/s-0044-1787189","article-title":"Strategies for performing factor assays in the presence of emicizumab or other novel\/emerging hemostatic agents","volume":"50","author":"Kershaw","year":"2024","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2024.12.034_bib18","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1055\/s-0038-1646007","article-title":"Measurement of low molecular weight heparin ex\u00a0vivo activities in clinical laboratories using various anti-Xa assays: interlaboratory variability and requirement for an agreed low molecular weight heparin standard","volume":"58","author":"Si\u00e9","year":"1987","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.034_bib19","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1055\/s-0037-1619662","article-title":"Uberwachung der Antikoagulanzientherapie mit Fondaparinux. Bestimmung der Anti-Faktor-Xa-Spiegel [Monitoring anticoagulation by fondaparinux: determination of anti factor Xa-level]","volume":"25","author":"D\u00e4mgen-von Brevern","year":"2005","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jtha.2024.12.034_bib20","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/9511499","article-title":"To measure or not to measure: direct oral anticoagulant laboratory assay monitoring in clinical practice","volume":"2023","author":"Ahuja","year":"2023","journal-title":"Adv Hematol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624007888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624007888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:38:25Z","timestamp":1777639105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624007888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1538783624007888"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.12.034","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Accurate evaluation of factor VIII activity of efanesoctocog alfa in the presence of emicizumab","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.12.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}